RNAseq of rhabdomyosarcoma cells after treatment with SGI-110 and/or Dasatinib

Patients with metastatic or recurrent rhabdomyosarcoma, the most common childhood soft tissue sarcoma, continue to do poorly and new treatments are needed. In this study we evaluated a novel combination therapy using a dna methyltransferase inhibitor, SGI-110, and the SRC family kinase inhibitor, Dasatinib. To understand the transcriptional changes that occur after treatment with SGI-110 with and without Dasatinib we performed RNAseq on two human RMS cell lines (Rh30 and RD) after 5 days of drug treatment. RNAseq was performed on Rh30 and RD human rhabdomyosarcoma cell lines treated with 0.5µM SGI-110, Dasatinib, or combination for 5 days in biological triplicates.